Keyword: CRISPR Therapeutics
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.
Two new studies show that CRISPR editing could raise the risk of edited cells developing tumors.
Shares in CRISPR fell 15% as investors digested the delay to the start of the gene-editing startup’s first U.S. clinical trial.
Mammoth Biosciences is developing a CRISPR-based platform to detect any biomarker containing DNA or RNA.
Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.
Inscripta offers its CRISPR enzymes for free, but the biotech plans to make its money selling CRISPR tools.
CRISPR is a promising treatment for blood disorders, but it comes with challenges, such as off-target effects.
Longtime Catalent CFO joins Allergan, Arcturus board and ousted CEO exchange fire, Lilly diabetes executive jumps to MannKind.
News of Lundberg’s departure emerged on the same day Celgene revealed it has sold another chunk of its once-double-digit stake in the startup.
A new journal paper has found that the CRISPR-Cas9 gene-editing technique could be under threat from the body’s own immune system.